← Back to Treatments
🏅 FDA Orphan Designation

Ceredase

Alglucerase injection

Manufacturer: Genzyme Corporation

Indicated for:
Fetal Gaucher diseaseOrphanGaucher disease

FDA-Approved Indications (2)

Fetal Gaucher diseaseOrphan Designation

Long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result i

Long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result i

Population: children, adolescents, and adults

Indications & Usage

Long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in one or more of the following conditions: a) moderate-to-severe anemia; b) thrombocytopenia with bleeding tendency; c) bone disease; d) significant hepatomegaly or splenomegaly.

💙 Support Programs

View all →
Ceredase
Genzyme Corporation

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.